Research programme: Pim kinase inhibitors - Jasco Pharmaceuticals

Drug Profile

Research programme: Pim kinase inhibitors - Jasco Pharmaceuticals

Alternative Names: JP 11646; JP_11646; Pim inhibitors

Latest Information Update: 21 Apr 2016

Price : $50

At a glance

  • Originator Jasco Pharmaceuticals
  • Developer Jasco Pharmaceuticals; Roswell Park Cancer Institute
  • Class Small molecules
  • Mechanism of Action Proto oncogene proteins c pim 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 14 Apr 2016 Drug interactions data from a preclinical study in Acute myeloid leukaemia presented at the 107th Annual Meeting of the American Association for Cancer Research (AACR-2016)
  • 31 May 2013 Preclinical development is ongoing in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top